Insights from the 2026 TT Life Sciences MedTech Clinical Network Conference in Brussels
Advancing Strategy, Compliance, and Innovation in the New Clinical Era
The 2026 MedTech Clinical Network Conference, hosted by TT Life Sciences in Brussels, brought together clinical leaders from across Europe at a pivotal time for the MedTech sector. Rather than simply revisiting regulatory updates, this year’s discussions focused on a broader challenge: how organisations can navigate uncertainty, strengthen clinical strategy, and generate evidence that delivers both regulatory assurance and commercial value.
In this short piece, Purdie Pascoe’s Post Market Survey experts share their key insights and takeaways.
Real-World Evidence must be defensible
Another key takeaway was that clinical evidence must meet both quality and quantity standards to withstand MDR scrutiny. Real-World Evidence (RWE) is no longer just supportive; it is increasingly central to conformity assessment. Manufacturers must ensure data is methodologically robust, clinically relevant, representative of EU practice, and collected through systematic, well-defined approaches.
Registries, insurance databases, electronic health records, and structured post market surveys can all provide valid evidence, but only when backed by clear protocols and justified sample sizes. Poorly designed or biased datasets, regardless of volume, risk undermining regulatory confidence. The question has shifted from “Do you have post-market data?” to “Can you defend its adequacy, relevance, and applicability?” Organisations that proactively design EU-aligned RWE strategies are far better positioned to navigate conformity assessments than those relying on loosely aligned or retrospective evidence.
PMCF Surveys front and centre
Post Market Clinical Follow-Up (PMCF) Surveys were one of the most discussed topics across the two days. The message was clear: surveys can be efficient and cost-effective, but only when strategically planned, methodologically robust, and designed with regulatory defence in mind. Under the MDR, informal or “trial and error” approaches are no longer acceptable.
Manufacturers must ensure PMCF activities are prospectively planned, built on validated methodologies, and designed to generate clinically relevant, representative data suitable for EU-MDR submissions. Regulators scrutinise not just the presence of data, but the rigour behind how it was generated. Several sessions reflected on how approaches evolved during the early MDR rollout, when organisations had more flexibility to refine processes. That window has now closed. Poorly designed surveys are not merely inefficient, they present regulatory risk.
Audience questions highlighted ongoing uncertainty around implementation. The takeaway: PMCF surveys must be treated as structured evidence-generation tools, not compliance afterthoughts.
Scientific merit alone is not enough
Clinical evidence must reduce regulatory uncertainty and deliver tangible value for patients, clinicians, and the wider portfolio.
In the session “Clinical Evidence Must Win Executive Buy-In,” John McDonald emphasised that strong clinical programmes are defined not just by endpoints, but by the clarity of the value they create and the risks they mitigate. Executives make decisions across portfolios, not individual programmes. Scientific strength alone cannot secure funding if the value proposition is unclear, risk mitigation is not visible, or timelines lack predictability.
Misalignment carries real cost. Duplicate studies, late discovery of data gaps, and missed opportunities to leverage evidence across programmes can dilute return on investment and erode confidence. Clinical programmes should therefore enable reimbursement and market access, drive adoption and differentiation, generate evidence across markets and submissions, and support label expansion where appropriate. Regulatory compliance should be the foundation, not the ceiling.
This requires robust, strategically aligned data collection. At Purdie Pascoe, we partner with MedTech manufacturers to ensure post market surveys are strategically aligned assets, not isolated compliance activities. By generating proportionate real-world data, we help organisations strengthen executive confidence while driving both regulatory assurance and commercial performance.
MDR uncertainty continues to shape strategy
The conference highlighted ongoing uncertainty around the EU MDR and its latest updates. Over the past three years, the regulatory landscape has changed significantly, with recent amendments focusing on increased digitalisation, alignment with other legislation, and improved coordination between notified bodies, experts, and agencies.
These changes have created a sense of flux, as stakeholders continue to clarify their roles. Consultation on the latest updates remains open until translations are complete, with deadlines repeatedly extended. Clear and proactive communication is therefore essential to mitigate the impact of this transitional period and ensure organisations can navigate evolving requirements effectively.
Final reflections
The 2026 TT Life Sciences MedTech Clinical Network Conference highlighted that the industry is shifting from reactive compliance to proactive, strategically aligned evidence generation. PMCF surveys must be robust, RWE must be defensible, and clinical programmes must demonstrate value beyond endpoints. Clear communication (across organisations and the wider ecosystem) has never been more important.
Organisations that combine methodological rigour with strategic clarity will be best positioned to thrive in this evolving regulatory landscape. At Purdie Pascoe, we don’t just conduct surveys, we partner closely with each of our clients. Our Post Market Survey team is trusted across the industry and brings unmatched expertise, having successfully executed over 500 surveys since 2019. We combine deep technical knowledge with a genuine commitment to understanding each client’s unique needs.
By delivering strategically designed surveys, we provide robust, defensible real-world evidence that strengthens regulatory assurance, supports commercial performance, and ensures MedTech companies continue to meet the needs of the patients and clinicians who rely on them most. With Purdie Pascoe as your partner in Post Market Surveys, you gain more than data, you gain a trusted team invested in your success.